CCA
JAZZ icon

Childress Capital Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Childress Capital Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-122
Closed -$20K – 554
2020
Q4 		$20K Buy
+122
New +$18.2K 0.01% 356

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Childress Capital Advisors's JAZZ Position: Q1 2021 in Review

Childress Capital Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2021, closing a stake of 122 shares — an estimated $20K sold.

Childress Capital Advisors first reported a position in JAZZ in Q4 2020 and held it in 1 quarter. The position peaked at $20K in Q4 2020. 442 funds tracked by Wall St. Rank hold JAZZ as of Q1 2021.

  • Childress Capital Advisors reported no remaining Jazz Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Childress Capital Advisors sold 122 Jazz Pharmaceuticals shares in Q1 2021, an estimated $20K.
  • Childress Capital Advisors first reported a position in Jazz Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Childress Capital Advisors's Jazz Pharmaceuticals position peaked at $20K in Q4 2020.
  • 442 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2021.

Based on Childress Capital Advisors's 13F filing for Q1 2021, filed 21 May 2021.